Back to News
Market Impact: 0.15
ArriVent BioPharma, Inc. Announces Initial Phase 1 Data for CDH17-Targeted ADC ARR-217
Source: Nasdaq
Healthcare & BiotechCorporate Guidance & Outlook
ArriVent BioPharma announced initial Phase 1 results for ARR-217 (MRG007), a cadherin-17-targeting antibody-drug conjugate developed with Lepu Biopharma. The results were presented at the European Society for Medical Oncology Congress 2026, but the provided article text cuts off before reporting the findings or any numerical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- EQT becomes the nation’s leading natural gas ‘juggernaut’ with a $13B deal as data center, export demand surges
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Anthropic IPO Filing Day Comes With Warning
- Celestica stock surges 10% after earnings beat as AI demand boosts 2027 outlook
- JetBlue posts bigger loss on fuel costs, but CEO says margins improving
- Humanity can't afford not to spend $800B on AI, Anthropic insists